Rizika dlouhodobé antisekreční terapie

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Risk of long-term antisecretory treatment with proton pum inhibitors
Authors

KROUPA Radek DOLINA Jiří

Year of publication 2010
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Other specializations of internal medicine
Keywords proton pump inhibitors - antacids - gastroesophageal reflux disease - treatment - adverse events
Description At present, pharmacoteraphy leading to a reduction in hydrochloric acid production in the stomach constitutes the core treatment strategy for the majority of the upper intestinal tract disease. Proton pump inhibitors (PPIs) are the predominant therapeutic group. Gastroesophageal reflux disease is the main indication for the long-term PPI use. Chronic use might be associated with adverse reactions. Potential risks take a form of malabsorption of certain food nutrients with their consequent deficiency, bacterial overgrowth and increased incidence of infections as well as altered regulation of proliferation of gastric as well other mucosas. Individual risk are low, their assessment is mostly based on the results of population studies. Even though the treatment benefits outweigh any potential theoretical risk, it is wise to decide well on the correct indication and to prescribe the lowest effective dose.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.